NIH R01 · 2024
Colistin resistance in extensively drug-resistant Gram-negative pathogens
Extensive drug resistance (XDR) in Gram-negative bacteria is widely recognized as a top priority public health issue. Colistin is often the only viable treatment option for infections caused by such pathogens, but morbidity and mortality are substantial even with colistin treatment. Furthermore, clinical use of colistin has led to the emergence of colistin-resistant strains. We have shown, for Acinetobacter baumannii and Klebsiella pneumoniae, that colistin resistance arises during therapy primarily due to modifications of lipid A, the membrane anchor component of the Gram-negative lipopolysaccharide, with amino-containing moieties such as aminoarabinose and phosphoethanolamine, and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.